Labiotech.eu

News and Trends 10 Apr 2017

The Biggest European Medtech Exit of 2017 Just Happened

The medtech company Symetis, specialized in heart valve replacements, today announced its acquisition by Boston Scientific in a hefty €411M ($435M) deal. Symetis is a Swiss medtech company and one of the key players on the European transcatheter aortic valve implantation (TAVI) market. After launching a promising €55M IPO on Euronext Paris in March, the company has now […]

April 10, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 10 Apr 2017

Swiss-Danish Collaboration will use Synbio to Produce a B Vitamin

Two startups in the fields of synthetic biology, Biosyntia and FGen, have struck a partnership to identify promising microbial strains. The objective is to find a strain that enables bioproduction of a B vitamin. The driving force of this new partnership between Biosyntia, Denmark, and ETH Zurich, and brands itself as a CRO for biologics […]

April 10, 2017 - 2 minutesmins - By Denise Neves Gameiro

Interview 10 Apr 2017

“Alzheimer’s is the Last Unclaimed Therapeutic Space,” says TauRx exec

The Alzheimer’s field has been hit with a number of failures. I spoke to the COO/CBO of TauRx, whose alternative approach may yet succeed. Pharma is throwing all it can at the problem of Alzheimer’s Disease without any success to show for its efforts. Now the sixth leading cause of death across all age groups, […]

April 10, 2017 - 7 minutesmins - By Evelyn Warner

More News! 8 Apr 2017

These Scientists are Turning the Human Brain into Art

Neuroimaging artist duo DiMa takes the popular saying “beauty is inside” to another level by transforming complex visualizations of the brain into art. Diana Roettger and Matthew Rowe, who work together under the artistic name DiMa, are two imaging scientists that create art directly from scientific research. Originally from Germany and the UK, respectively, both hold […]

April 8, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

More News! 7 Apr 2017

This Biotech Mining Probiotics to Treat the Skin has IPO’d in London

SkinBioTherapeutics has raised £4,5M in its IPO on the London Stock Exchange to advance its probiotic technology for skin health applications. SkinBioTherapeutics, a spin-out from the University of Manchester, made its debut this week in AIM, the London Stock Exchange’s market for smaller growing companies. The £4,5M (€5.25M) raised will be used to continue the development […]

April 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Apr 2017

This New Biotech counts with the Largest Antibiotic Resistance Database

Curetis has launched Ares Genetics, a company that will use the biggest antibiotic resistance genetic database to advance the diagnose of infections. Ares Genetics, the new subsidiary of Curetis, will investigate the genetic foundation of antibiotic resistance to develop new approaches for the rapid diagnose of specific resistance in patients with infections, as well as tools to […]

April 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Apr 2017

Evotec and Sanofi Hit the First Milestone for a Diabetes Cell Therapy

Evotec and Sanofi have achieved preclinical proof-of-concept for a new beta cell therapy for diabetes, triggering a €3M milestone payment from Sanofi. In 2015, Sanofi and the German CRO Evotec partnered to jointly develop a beta cell replacement therapy for the treatment of diabetes in a deal that could reach more than €300M in potential milestone payments. […]

April 6, 2017 - 2 minutesmins - By Melanie De Almeida

More News! 6 Apr 2017

Fear & Loathing in GMOs: How do you change concerned minds?

The house was packed to hear Joyce Tait of the Innogen Institute and Mark Lynas, an environmental writer, speak about smarter approaches to GM regulations. The second day of SynBioBeta yesterday started early, but fuelled by a passion for synthetic biology (on which a number of speakers commented), attendees packed into the lecture hall for a fireside chat on GMO regulation with Joyce […]

April 6, 2017 - 5 minutesmins - By Evelyn Warner

News and Trends 6 Apr 2017

Biotech Targeting Tau-Tangles in Neurodegeneration Initiates Clinical Trials

Swiss Asceneuron has received regulatory approval to start its first Phase I trial of ASN120290, which is indicated for the treatment of dementia. Asceneuron was founded in 2012 as a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio. Its key asset ASN120290 is an inhibitor of the O-GlcNAcase enzyme and is indicated for the treatment of diseases associated […]

April 6, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 6 Apr 2017

UPDATE: Norwegian Stock Exchange hits Record Biotech IPO

UPDATE (06/04/2017): BerGenBio has raised €43.55M, successfully beating a biotech record on the Norwegian stock exchange and setting its market cap at €135M. UPDATE (28/03/2017): BerGenBio has announced that the IPO could run up to €44M on Oslo Børs. It could become the Norway stock exchange’s biggest IPO in biotech, and indeed €44M would make it […]

April 6, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 6 Apr 2017

How is Biotech Transforming Pharma’s R&D Model?

Since the early 2000s, pharma has undergone a major reorganization. What roles do strategic alliances and acquisitions play in this new model? For almost two centuries, medicinal products have brought continuous therapeutic progress. This path is marked by breakthrough innovations, which now allow us to treat diseases previously believed to be incurable. But to bring about […]

April 6, 2017 - 4 minutesmins - By External Contributor

Heptares AstraZeneka AZD4635 checkpoint inhibitor

News and Trends 5 Apr 2017

Heptares Takes Home €11M for its Next-Generation Checkpoint Inhibitor

Heptares Therapeutics has achieved a new milestone in its immuno-oncology collaboration with AstraZeneca triggering an €11M payment from AstraZeneca. Heptares has announced the wrap-up of its preclinical programme for a new checkpoint inhibitor, AZD4635 that reverses adenosine-mediated T cell suppression and enhances anti-tumor immunity. The British company will now receive an €11M ($12M) milestone payment from AstraZeneca, who obtained exclusive global rights […]

April 5, 2017 - 3 minutesmins - By Melanie De Almeida

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The Biggest European Medtech Exit of 2017 Just Happened

Swiss-Danish Collaboration will use Synbio to Produce a B Vitamin

“Alzheimer’s is the Last Unclaimed Therapeutic Space,” says TauRx exec

These Scientists are Turning the Human Brain into Art

This Biotech Mining Probiotics to Treat the Skin has IPO’d in London

This New Biotech counts with the Largest Antibiotic Resistance Database

Evotec and Sanofi Hit the First Milestone for a Diabetes Cell Therapy

Fear & Loathing in GMOs: How do you change concerned minds?

Biotech Targeting Tau-Tangles in Neurodegeneration Initiates Clinical Trials

UPDATE: Norwegian Stock Exchange hits Record Biotech IPO

How is Biotech Transforming Pharma’s R&D Model?

Heptares Takes Home €11M for its Next-Generation Checkpoint Inhibitor

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!